Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

TLDR

Axillary node involvement and estrogen receptor negativity at diagnosis suggest aggressive disease and may predict shorter survival after relapse. Survival after recurrence depends on the initial recurrence site and is further independently influenced by estrogen receptor status, axillary node status, and disease‑free interval; ER‑negative tumors tend to recur in visceral/soft‑tissue sites and have poorer survival, whereas ER‑positive tumors recur in bone and have longer survival.

Abstract

Univariate and multivariate analyses of potential prognostic factors for 1,015 women with recurrent breast cancer confirmed that the site of initial recurrence is an important determinant for predicting survival from the time of initial recurrence. However, both estrogen receptor (ER) status and axillary lymph node status at diagnosis, as well as the length of the disease-free interval, provide additional independent information for predicting patient survival after disease recurrence. Involved axillary lymph nodes at the time of initial diagnosis and/or lack of ERs may indicate a highly malignant tumor or a weak host defense, either of which might be related to short survival after relapse. Patients with ER-negative tumors recurred more often in visceral and soft-tissue sites, while patients with ER-positive tumors were more likely to recur in bony sites. However, for each metastatic site, receptor-positive patients had longer survival